


156 patients included in both groups



Efigure S1

In all, 170 patients with multiple sclerosis were sampled during interferon beta (IFN $\beta$ ) treatment at time point 1 (t1) and t2. Median time between sampling was 13 months. The 170 patients in the IFN $\beta$  subgroup were subsequently treated with natalizumab (NAT). The NAT group consisted of 156 of these patients and 558 additional patients with MS initiating NAT therapy (n=714). The paired serum samples from the 714 patients in the NAT group were obtained immediately prior to the first infusion of NAT, at time point 3 (t3) and the last available sample during NAT treatment, at time point 4 (t4). Median time between sampling was 12 months.